Benutzerspezifische Werkzeuge

Publikationsliste PD Dr. rer. nat. et rer. medic. habil. G. Gille


Meinel J*, Radad K*, Rausch W-D, Reichmann H, Gille G (2015) Cabergoline protects dopaminergic neurons against rotenone-induced cell death in primary mesencephalic cell culture. Folia Neuropathol., 53, 29-40.
*both authors contributed equally to the publication

Radad R, Scheller D, Rausch W-D, Reichmann H, Gille G (2014) Neuroprotective effect of rotigotine against complex I inhibitors, MPP+ and rotenone, in primary mesencephalic cell culture. Folia Neuropathol. 52, 164-178

Oster S, Radad K, Scheller D, Hesse M, Balanzew W, Reichmann H, Gille G (2014) Rotigotine protects against glutamate toxicity in primary dopaminergic cell culture. Eur. J. Pharmacol.724, 31-42. Epub 2013 Dec 21.

Pan-Montojo F, Schwarz M, Winkler C, Arnhold M, O'Sullivan GA, Pal A, Said J, Marsico G, Verbavatz JM, Rodrigo-Angulo M, Gille G, Funk RH, Reichmann H (2012) Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci. Rep.2, 898. Epub 2012 Nov 30.

Gruss M*, Appenroth D*, Flubacher A*, Enzensperger C, Bock J, Fleck C, Gille G*, Braun K* (2012) 9-Methyl-β-carboline-induced cognitive enhancement is associated with elevated hippocampal dopamine levels and dendritic and synaptic proliferation. J. Neurochem.121, 924-931. *these authors contributed equally to the publication

Polanski W, Enzensperger C, Reichmann H, Gille G (2010) The exceptional properties of 9-methyl-beta-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects. J. Neurochem. 113, 1659-1675. Epub 2010 Mar 31.

Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G, Spillantini MG, Reichmann H, Funk RH (2010) Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One, Jan 19;5(1):e8762

Hamann J, Wernicke C, Lehmann J, Reichmann H, Rommelspacher H*, Gille G* (2008) 9-Methyl-b-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture. Neurochem. Int. 52, 688-700.Epub 2007 Sep 4.
*both authors contributed equally to the publication

Radad K*, Gille G*, Rausch W-D. (2007) Dopaminergic neurons are preferentially sensitive to long-term rotenone toxicity in primary cell culture. Toxicol. In Vitro22, 68-74. Epub 2007 Sep 1.
*both authors contributed equally to the publication

Radad K * , Gille G* , Xiaojing J, Durany N, Rausch W-D. (2007) Citicholine reduces dopaminergic cell loss induced by MPP+ and glutamate in primary mesencephalic cell culture. Int. J. Neurosci.117, 985-998.
*both authors contributed equally to the publication

Hamann J, Rommelspacher H, Storch A, Reichmann H, Gille G. (2006) Neurotoxic mechanisms of 2,9-dimethyl- b -carbolinium in primary dopaminergic culture. J. Neurochem.98, 1185-1199. Epub 2006 June 19.

Radad K, Rausch W-D, Gille G. (2006) Rotenone induces dopaminergic cell death by increasing ROS production and inhibiting mitochondrial respiration. Neurochem. Int. 49 , 379-386. Epub 2006 Mar 31.

Radad K, Gille G, Liu L, Rausch W-D. (2006) Use of ginseng in medicine with emphasis on neurodegenerative disorders. J. Pharmacol. Sci.100, 175-186. Epub 2006 Mar 4.

Pavlovic S, Schulze G, Wernicke C, Bonnet R, Gille G, Badiali L, Kaminska A, Lorenc-Koci E, Ossowska K, Rommelspacher H. (2006) 2,9-Dimethyl-β-carbolinium, a neurotoxin occurring in human brain, is a potent inducer of apoptosis as 1-methyl-4-phenylpyridinium (MPP+) . Neuroscience 139, 1525-1537. Epub 2006 Mar 3.

Mehler-Wex C, Grünblatt E, Zeiske S, Gille G, Rausch D, Warnke A, Gerlach M. (2006) Microarray analysis reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes. J. Neural Transm. 113, 1383-1393. Epub 2006 Feb 9.

Gille G *, Radad K*, Reichmann H., Rausch W-D. (2006) Synergistic effect of a -dihydroergocryptine and L-DOPA or dopamine on dopaminergic neurons in primary culture. J. Neural Transm. 113 , 1107-1118. Epub 2005 Oct 27.
*both authors contributed equally to the publication

Radad K, Gille G, Moldzio R, Rausch W-D. (2004) Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate. Brain Res. 1021, 41-53.

Gille G , Hung S-T, Reichmann H, Rausch W-D. (2004) Oxidative stress to dopaminergic neurons as models of Parkinson's disease. Ann. NY Acad. Sci. 1018 , 533-540.

Radad K, Gille G, Moldzio R, Saito H, Ishige K, Rausch W-D. (2004) Ginsenosides Rb1 and Rg1 effects on survival and neurite growth of MPP+-affected mesencephalic dopaminergic cells. J. Neural Transm.111, 37-45. Epub 2003 Dec 3.

Menke T*, Gille G*, Reber F, Janetzky B, Andler W, Funk RH, Reichmann H. (2003) Coenzyme Q10 reduces the toxicity of rotenone in neuronal cultures by preserving the mitochondrial membrane potential. Biofactors 18, 65-72.
*both authors contributed equally to the publication

Franz A, König F, Anglmayer M, Rausch-Fan X, Gille G, Rausch W-D, Lucas T, Sperr W, Schedle A. (2003) Cytotoxic effects of packable and nonpackable dental composites. Dent.Mater.19, 382-392.

Ngyuen A, Gille G, Moldzio R, Hung S-T, Rausch W-D. (2002). Synthetic neuromelanin is toxic to dopaminergic cell cultures. J. Neural Transm.109, 651-661.

Gille G , Rausch W-D, Hung S-T, Moldzio R, Janetzky B, Hundemer HP, Kolter T, Reichmann H. (2002). Pergolide protects dopaminergic neurons in primary culture under stress conditions. J. Neural Transm.109, 633-643.

Gille G , Rausch W-D, Hung S-T, Moldzio R, Ngyuen A, Janetzky B, Engfer A, Reichmann H. (2002). Protection of dopaminergic neurons in primary culture by lisuride. J. NeuralTransm.109 , 157-169.

Gille G , Pabst T, Janetzky B, Bringmann G, Reichmann H, Rausch W-D. (2000). Neurotrophic effects of simplified mastigophorene analogs on mesencephalic dopaminergic cells in primary culture. Drug Dev. Res.50, 153-156.

Janetzky B, Gille G, Abdel-Mohsen M, God R, Rausch W-D, Bringmann G, Reichmann H. (1999). Effect of highly halogenated β -carbolines on dopaminergic cells in culture and on mitochondrial respiration. Drug Dev. Res.46, 51-56.

Sigler K; Gille G, Vacata V, Stadler N, Höfer M. (1998). Inactivation of the plasma membrane ATPase of Schizosaccharomyces pombe by hydrogen peroxide and by the Fenton reagent (Fe2+/H2O2): nonradical vs.radical-induced oxidation. Folia Microbiol.43, 361-367.

Sigler K, Gille G. (1998). Stability and refractoriness of the high catalase activity in the oxidative stress resistant fission yeast Schizosaccharomyces pombe. Folia Microbiol. 43, 369-372.

Gille G , Sigler K. (1994). Effect of H2O2-induced oxidative stress on some yeast membrane functions. Folia Microbiol.39, 518-519.

Janda S, Gille G, Sigler K., Höfer M. (1993). Effect of hydrogen peroxide on sugar transport in Schizosaccharomyces pombe. Absence of lipid peroxidation. Folia Microbiol.38, 135-140.

Gille G , Sigler K, Höfer M. (1993). Response of catalase activity and membrane fluidity of aerobically grown Schizosaccharomyces pombe and Saccharomyces cerevisiae to aeration and the presence of substrates. J. Gen. Microbiol.139, 1627-1634.

Gille G , Höfer M, Sigler K. (1992). Evidence for a specific fructose carrier in Rhodotorula glutinis based on kinetic studies with a mutant defective in glucose transport. Folia Microbiol.37, 31-38.


Rausch W-D, Wei-Ming L, Gille G, Radad K. (2007) Perspectives for ginsenosides in models of Parkinson’s disease. J. Ginseng Res.31, 127-136

Gille G , Reichmann H (2007) Ätiopathogenese des Morbus Parkinson. Der Neurologe und Psychiater 4, 13-14

Rausch WD, Liu S, Gille G, Radad K (2006). Neuroprotective effects of ginsenosides. Acta Neurobiol. Exp.66, 369-375.

Radad K, Gille G, Rausch W-D. (2005) Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson’s disease. Pharmacological Reports (formerly Polish Journal of Pharmacology)57, 701-712.

Gille G , Reichmann H. (2005) Ursachen des idiopathischen Parkinson-Syndroms – Stand 2005. Aktuelle Neurologie 32 [Suppl 3], S75-S87.

Radad K, Gille G, Rausch W-D. (2004) Use of ginseng in medicine: perspectives on CNS disorders. Iranian Journal of Pharmacology and Therapeutics3, 30-40

Rausch WD, Gille G, Riederer P. (2003) The dopaminergic neuron: A model system of Parkinson’s disease. Neurol. Croat. 52 [Suppl 2], 6-9.

Gille G , Sommer U, Reichmann H. (2003). Zauberwort Neuroprotektion. Der Neurologe undPsychiater 5, 41-43.

Radad K, Gille G, Moldzio R, Saito H, Ishige K, Rausch W-D (2003) Neuroprotektive Effekte von Ginsenosiden – Mechanismen in dopaminergen Zellkulturen. MedReport27, 6

Riederer P, Gille G, Müller T, Przuntek H, Reichmann H, Riess O, Schwartz A, Schwarz J, Vogt T (2002). Practical importance of neuroprotection in Parkinson’s disease. J. Neurol.249 [Suppl 3], 53-56.

Gille G , Sigler K. (1995). Oxidative stress and living cells. Folia Microbiol. 40, 131-152


Gille G, Riederer P. (2005) Dopamine and neurodegeneration. In: Dopamine and Glutamate in Psychiatric Disorders, W. J. Schmidt and M. E. A. Reith, eds. ( Totowa , NJ : Humana Press Inc.), 409-439